Caroline Belin, NP
Nurse Practitioner · Los Angeles, CANPI 1447769971
Payments from drug & device makers
Across 311 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$778
- Regeneron Healthcare Solutions, Inc.$623
- Sanofi$404
- GSK$402
- AstraZeneca$309
- plus $3K from 36 others
What the payments were for
- Food & beverage$7,58097%
- Education$2123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 85 | $1,974 |
| Gilead | 34 | $778 |
| Regeneron Healthcare Solutions, Inc. | 23 | $623 |
| Sanofi | 14 | $404 |
| GSK | 13 | $402 |
| AstraZeneca | 15 | $309 |
| Biocryst US Sales Co., LLC | 9 | $272 |
| Grifols USA, LLC | 11 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $238 |
| CSL Behring | 10 | $231 |
| EMD Serono, Inc. | 9 | $199 |
| Janssen Products, LP | 2 | $198 |
| Genentech USA, Inc. | 6 | $188 |
| Novartis | 6 | $175 |
| Alkermes, Inc. | 3 | $171 |
| Amarin Pharma, Inc. | 6 | $132 |
| Amgen | 5 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $121 |
| AbbVie | 4 | $98 |
| Napo Pharmaceuticals Inc | 4 | $98 |
| Alk-abello, Inc | 3 | $75 |
| Merck | 3 | $72 |
| Pharming Healthcare, Inc. | 3 | $66 |
| Novo Nordisk | 3 | $63 |
| Pfizer | 2 | $52 |
| Antares Pharma, Inc. | 2 | $51 |
| Kaleo, Inc. | 2 | $51 |
| Optinose US, Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $45 |
| Octapharma USA, Inc. | 1 | $35 |
| Tolmar, Inc. | 2 | $33 |
| Corium, LLC | 1 | $31 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Bausch Health US, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$125
How this compares
$7,792 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 12 | $51,363 |
| Epinephrine | 55 | $9,698 |
| Cromolyn Sodium | 11 | $3,521 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,734 |
| Azelastine Hcl | 84 | $1,771 |
| Levocetirizine Dihydrochloride | 160 | $1,043 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $988 |
| Fluticasone Propionate | 47 | $879 |
| Famotidine | 53 | $862 |
| Ipratropium Bromide | 35 | $850 |
| Montelukast Sodium | 41 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Arnuity Ellipta | $402 | $54,09625 claims |
| Hikma Pharmaceuticals USAEpinephrine | $24 | $9,69855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Los Angeles
- Kristin HorwoodLos Angeles$99K
- Yunying ChenLos Angeles$80K
- Lauren BristowLos Angeles$46K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.